TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory acute myeloid leukemia patients without severe complications such as active infections and bleedings; ECOG score less than 3.~Exclusion Criteria:~* Inablity to tolerate inducton chemotherapy; life expectancy less than 1 month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CDIAG (Type: EXPERIMENTAL): Relapsed or refractroy acute myeloid leukemia patients reveive chidamide, decitabine combined with priming IAG regimen treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Between 6 and 11 years~* Autism Spectrum Disorder~* Attention Deficit Hyperactivity Disorder~* Stimulant medication-free at study entry~* No clinically significant abnormalities that preclude safe participation~* Sufficient developmental level (\~3 yrs)~* Able to keep appointments~* Able to communicate effectively~* Teacher cooperation~Exclusion Criteria:~* Received an investigational medication in the previous 30 days~* Current medication treatment is effective and well-tolerated~* Medical conditions that affect patient safety~* MAOIs within one month~* Hypertension~* Bipolar disorder or psychosis~* Anticonvulsants~* Psychotropic medication or health food supplement~* Tourette Disorder~* Seizure disorder~* Neurological condition~* Structural heart disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (Type: EXPERIMENTAL): 10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Activity of Platelet Inhibitor Drugs Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients presenting within 12 hours from the onset of symptoms with STEMI~2. Informed, written consent~Exclusion Criteria:~1. Age \< 18 years~2. Active bleeding; bleeding diathesis; coagulopathy~3. History of gastrointestinal or genitourinary bleeding \<2 months~4. Major surgery in the last 6 weeks~5. History of intracranial bleeding or structural abnormalities~6. Suspected aortic dissection~7. Any previous TIA/stroke~8. Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux, GPI.~9. Known relevant hematological deviations: Hb \<10 g/dl, Platelet count \<100x10\^9/l~10. Use of coumadin derivatives within the last 7 days~11. Chronic therapy with prasugrel or ticagrelor~12. Known malignancies or other comorbid conditions with life expectancy \<1 year~13. Known severe liver disease, severe renal failure~14. Known allergy to the study medications~15. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prasugrel loading dose (Type: ACTIVE_COMPARATOR): None
- Ticagrelor Loading dose (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fish Oil (Omega 3), Immune Function, and Mood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Recruiting men and women ages 40-88 from the Greater Columbus Ohio area. Participation involves taking capsules for 4 months and completing 6 appointments (for a total of 19.5 hours) at Ohio State.~Inclusion Criteria:~* Healthy men and women~* NOT currently taking any sort of fish oil or omega 3 supplement~Exclusion Criteria:~* Use of blood pressure medicines, cholesterol-lowering drugs, steroids, or antidepressants~* Certain lifestyle habits such as smoking or exercising vigorously for 2 or more hours a week may also exclude applicants from participating

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 88 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 1.25 g/d
- 2 (Type: EXPERIMENTAL): 2.496 g/d
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Children and adolescents who experience delayed MTX-clearance and renal dysfunction during high-dose methotrexate treatment in NOPHO ALL-2008.~Exclusion Criteria:~Children and adolescents with earlier anaphylactic reaction to Glucarpidase. Pregnant patients.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Glucarpidase arm (Type: EXPERIMENTAL): In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IVPCA in the Management of Pain Following Major Intracranial Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults undergoing intracranial surgery~Exclusion Criteria:~* Patient refusal~* Pregnancy~* Aphasia~* Respiratory failure~* Allergy/intolerance to fentanyl~* Opioids use~* History of opioid-dependent pain,~* Patient has been in an investigational drug trial (except chemotherapy) in the month preceding the day of enrollment~* Mental or physical limitations that would prevent patient assessment or PCA use~* Chronic painful conditions unrelated to the reason for surgery,~* Clinically significant respiratory disease that required supplemental oxygen or ventilatory support such as use of mechanical ventilation or positive pressure ventilation~* Patient is unable to initiate a bolus dose of IVPCA fentanyl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supratentorial PCA fentanyl (Type: EXPERIMENTAL): None
- Supratentorial PRN fentanyl (Type: ACTIVE_COMPARATOR): None
- Infratentorial PCA fentanyl (Type: EXPERIMENTAL): None
- Infratentorial PRN fentanyl (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or greater~2. Diagnosis of suspected thrombotic thrombocytopenic purpura (TTP)~   1. Platelet count of \< 80,000 for newly diagnosed patients and \< 120,000 for relapsed patients~  2. Microangiopathic hemolytic anemia with RBC fragmentation~  3. LDH \>1 x ULN~3. Subjects who will receive treatment for TTP with plasma exchange~4. Subjects who have not started the 5th plasma exchange~5. Plasma ADAMTS13 activity \<10%~Exclusion Criteria:~1. Treatment for TTP within the past 2 months~2. Severe active infection indicated by sepsis (requirement for pressors with or without positive blood cultures) or clinical evidence of enteric infection with E. coli O157:H7 or related organism~3. Currently under treatment for cancer (subjects with localized skin carcinoma will be accepted)~4. Microangiopathic hemolytic anemia due to a mechanical heart valve~5. Severe hypertension, as defined by systolic BP \>180 AND diastolic BP \>120, or papilledema~6. Organ or stem cell transplant~7. Use of calcineurin inhibitors (sirolimus, tacrolimus, cyclosporin A) within 6 months prior to diagnosis of TTP~8. Disseminated intravascular coagulation as defined by:~   a. INR \>2.0 (unrelated to anticoagulation, unresponsive to Vitamin K) or b. Fibrinogen \<100 mg/dl~9. Pregnancy~10. Known congenital TTP.~11. Rituximab within the previous year.~12. HIV history or positive serology~13. History of hepatitis B or positive serology for HBsAg or Anti-HBc~14. Persistent or unexplained platelet count below 150,000/μL within 3 months of current TTP presentation~15. Hypersensitivities or allergies to murine and/or humanized antibodies~16. Current participation in trials of investigational therapies or devices, other than central catheters

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- low dose rituximab (Type: EXPERIMENTAL): this is a single-arm trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age at least 18 years at the time of signing informed consent. Algeria: Male or female, age at least 19 years at the time of signing informed consent~* Subjects diagnosed (clinically) with type 2 diabetes mellitus prior to day of screening (Visit 1)~* Treated with any pre-mix/self-mix or basal insulin regimen for at least 90 days prior to the day of screening (Visit 1)~* Subjects not on any OAD(s) (oral anti-diabetic drug) prior to trial participation OR subjects on fixed daily dose(s) of OAD(s) for at least 90 days prior to screening (Visit 1). The OAD(s) include any of the following anti-diabetic drug(s)/regimen: Biguanides (metformin equal to or above 1500 mg or maximum tolerated dose documented in the subject medical record) Insulin secretagogues (sulfonylureas (SU) and glinides), Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), a-glucosidase inhibitors, Sodium-glucose co-transporter 2- inhibitors (SGLT2 Inhibitors ) (above or equal to half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record)~* HbA1c 7.0%-10.0% (53-86 mmol/mol) (both inclusive, by central laboratory analysis)~* Intention to fast (daytime, i.e., between dawn and sunset) during Ramadan after receiving medical counselling regarding the risk of fasting~* Willing to give blood during Ramadan~Exclusion Criteria:~* Any contraindication for successful and sustained fasting from a medical perspective at the discretion of the investigator (such as acute illness, severe hypoglycaemia within 90 days prior to screening (Visit 1), hypoglycaemia unawareness, ketoacidosis within 90 days prior to screening (Visit), hyperosmolar hyperglycaemic coma within 90 days prior to screening (Visit 1), subjects performing intense physical labour)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegAsp U100 BID (Type: EXPERIMENTAL): None
- BIAsp U100 BID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lipid Efficacy/Tolerability Study (0524A-020)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 to 85 years of age with Primary Hypercholesterolemia or Mixed Hyperlipidemia with LDL-C below 100 mg/dL for high risk patients (patients with Coronary Artery Disease (CHD).~* Have medical conditions considered to be CHD equivalent).~* LDL-C below 130 mg/dL for patients with multiple risk factors.~* LDL-C between 130 and 190 mg/dL for patients with low risk and Triglycerides \</= to 350 mg/dL.~Exclusion Criteria:~* A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study, patients \< 20% compliance, patients with chronic medical conditions, patients with unstable doses of medications.~* Pregnant or lactating women, or women intending to become pregnant are excluded.~* Patient with diabetes mellitus that is poorly controlled, newly diagnosed, has recently experienced repeated hypoglycemia or unstable glycemic control, or is taking new or recently adjusted antidiabetic pharmacotherapy (with the exception of +/- 10 units of insulin).~* Patients with the following conditions: chronic heart failure, uncontrolled/unstable cardiac arrhythmias, unstable hypertension, active or chronic hepatobiliary or hepatic disease, HIV positive, gout (within 1 year).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of advanced liver cancer adequate bone marrow, liver and kidney function~* Any local therapy for tumor must have been completed at least 4 weeks prior to enrolling in study~Exclusion criteria:~* Pregnant or breastfeeding~* Any serious or unstable medical or psychiatric conditions~* History of metastases to central nervous system~* History of ulcer, inflammatory bowel disease or disease of the gut~* History of HIV, or uncontrolled infection~* Have had a cardiac condition or stoke during the past 6 months~* High blood pressure~* Have had a blood clot during the past 6 months~* History of bleeding blood vessels

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib Arm (Type: EXPERIMENTAL): Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Prediction of Prolonged Labour

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primi gravidae~* \>37th week~* Cephalic presentation~* Prolonged first stage according to WHO definitions.~Exclusion Criteria:~* Multiple pregnancies~* Intrauterine fetal death

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound examination (Type: None): Women with prolonged Labour; Primi gravidae, single pregnancy, \>37 weeks, fetus alive, cephalic presentation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the following European Spondyloarthropathy Study Group Criteria:~  1. inflammatory spinal pain OR~ 2. synovitis AND~ 3. one or more of the following:~     1. positive family history~    2. urethritis or cervicitis within 1 month prior to onset of arthritis~    3. buttock pain~    4. enthesopathy~    5. sacroiliitis~* Disease duration of at least 6 months~* Negative pregnancy test at study baseline and willing to use an effective method of contraception other than combined oral contraceptives for the duration of the study (for women of childbearing age)~Exclusion Criteria:~* Sensitivity or history of allergic reaction to rifampin, doxycycline, or azithromycin~* Currently taking any medications that may interact with the study medications, specifically rifampin~* Liver transaminases greater than or equal to two times the normal level~* Significant abnormalities in the complete blood count (CBC)~* Pregnant~* Current psoriasis~* Diagnosis of inflammatory bowel disease~* Diagnosis of ankylosing spondylitis~* Previous prolonged exposure to antibiotics (more than 2 weeks) as a potential treatment for reactive arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin and Rifampin (Type: ACTIVE_COMPARATOR): Participants received Azithromycin and Rifampin
- Doxycycline and Rifampin (Type: ACTIVE_COMPARATOR): Participants received Doxycycline and Rifampin
- received placebo (Type: PLACEBO_COMPARATOR): Participants received placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed CF diagnosis with 2 clinical features~2. Documented history of EPI~3. Enteral formula use minimum of 4x/week~4. Written informed consent or assent, as applicable~Exclusion Criteria:~1. Uncontrolled diabetes mellitus~2. Signs and symptoms of liver cirrhosis or portal hypertension~3. Lung/liver transplant~4. Active cancer currently receiving cancer treatment~5. Crohn's or celiac disease, infectious gastroenteritis, sprue, lactose intolerant, inflammatory bowel disease~6. DIOS or fibrosing colonopathy

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- RELiZORB (Type: EXPERIMENTAL): Treatment (RELiZORB)
- Control (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trichomonas Vaginalis Recurrence Among HIV+ Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* 18 years or older~* HIV-positive~* TV positive by either wet preparation or culture~* ability to refrain from all alcohol use for 24 hours before and after taking oral metronidazole~* willing to take metronidazole treatment~Exclusion Criteria:~* pregnant~* incarcerated~* previously enrolled~* currently taking disulfiram~* alcoholism or known liver damage~* medical contraindications to metronidazole~* treated with metronidazole within the previous 14 days~* requires treatment for B.V. per Amsel's criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single dose (Type: ACTIVE_COMPARATOR): Metronidazole 2 gm single dose
- 7 day dose (Type: ACTIVE_COMPARATOR): Metronidazole 500 mg dose x 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of narcolepsy~* Good general health~* Willing and able to comply with the study design and schedule and other requirements~Exclusion Criteria:~* If female, pregnant or lactating~* Customary bedtime later than midnight~* History of significant medical condition, behavioral, or psychiatric disorder (including suicidal ideation), or surgical history~* Any other clinically relevant medical, behavioral or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness~* History of significant cardiovascular disease~* Body mass index \> 34~* Excessive caffeine use - \> 600 mg/day of caffeine or \> 6 cups of coffee/day~* History of alcohol or drug abuse within the past 2 years~* Nicotine dependence that has an effect on sleep

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ADX-N05 (Type: EXPERIMENTAL): ADX-N05 to be taken once a day for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match ADX-N05 to be taken once a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete